The FDA’s Oncologic Drugs Advisory Committee narrowly voted against the approval of Zusduri, citing the lack of a completely ...

The rehired staff, who number around 460, work with the CDC’s viral disease prevention efforts and sexual health testing labs ...

Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...

The biopharma job market failed to turn around in May, but employers were still hiring, especially in Indiana and California, ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...

Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article in JAMA on Tuesday outlining the FDA’s ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

The American Medical Association is also urging an “immediate reversal” of the HHS Secretary's decision to oust all 17 ...